ARCHIVES

Specific Pathology Pattern Can Predict Recurrence

This article is from The Cancer Letter archive.

Vol. 36 No. 8 | August 30, 2013

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

March 28, 2014

FDA will return memento given to McClellan by NCI Director Andrew von Eschenbach.

February 6, 2004

NCI Cooperative Group, Cancer Center Trials Listed

March 28, 2008

ODAC Clarifies Standards for Maintenance In Ovarian Cancer; Nixes Olaparib in 11-2 Vote

June 27, 2014

Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39

October 26, 2012

Price Increase

July 22, 1983